Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of sunitinib and gemcitabine in
treating patients with pancreatic cancer or other solid tumors. Sunitinib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood
flow to the tumor. Drugs used in hemotherapy, such as gemcitabine, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving sunitinib together with gemcitabine may kill more tumor cells.